In hypertensive rats, Ephx2 overexpression in penile endothelium suppresses the AKT/eNOS pathway; silencing it or giving icariin restored measurable erectile function
Journal: Journal of Sexual Medicine | Published: 2026-06-05 | Type: Animal Study | PMID: 42361223 Authors: Zhang Tao, Jiang Jun, Jiang Rui (Department of Urology, Affiliated Hospital of Southwest Medical University, Luzhou, China) Funding/COI: 2025 Sichuan Medical Association Research Project; 2024 China National Health Commission Research Project. COI: not disclosed.
Hypertension-related ED is common but the molecular mechanisms inside penile tissue are poorly mapped. This team used transcriptomics and proteomics on the corpus cavernosum of spontaneously hypertensive rats (SHRs) to identify Ephx2 — an enzyme that degrades vasoprotective epoxyeicosatrienoic acids — as significantly upregulated, and showed it suppresses the AKT/eNOS nitric oxide pathway. They then silenced Ephx2 two ways: with an AAV-delivered siRNA construct and with icariin, a flavonoid from Epimedium used in traditional Chinese medicine, both of which improved erectile function scores in the rats.
This is a mechanistically rigorous rodent study built on a solid hypothesis-generation pipeline: they didn't pick Ephx2 arbitrarily, they ran full transcriptome and proteome sequencing on the target tissue and filtered for genes correlated with eNOS pathway activity. Validation used four independent methods (Western blot, qPCR, immunohistochemistry, and in vivo erectile function measurement via intracavernous pressure). The SHR model is the most widely used hypertensive rat strain and is well-validated for vascular ED research.
The inclusion of two mechanistically distinct Ephx2-suppression strategies — genetic silencing versus a small molecule — is a genuine strength. It reduces the chance that the effect belongs to off-target AAV biology rather than Ephx2 itself. The ICPmax/MAP ratio is a standard and accepted measure of rat erectile function.
However, the abstract does not report group sizes, which is a notable omission. Without n-per-group, the P < 0.05 findings cannot be fully evaluated for statistical power. Icariin has known pleiotropic effects beyond Ephx2 — it inhibits PDE5 and acts on multiple signaling pathways — so interpreting it as a clean Ephx2 inhibitor requires caution.
This is competent preclinical biology. The multi-omics target identification + dual-intervention validation design is above average for a rodent ED paper, and the Ephx2/sEH angle is genuinely novel in the penile vascular context — sEH inhibitors have been explored in cardiovascular and renal disease but not widely in ED. The missing sample sizes and the icariin specificity problem are real weaknesses. The leap from "SHR gene silencing works" to "therapeutic approach" is long even by animal-study standards. Worth reading if you follow vascular ED mechanisms; not worth citing as clinical evidence for anything.